Taken together, our findings indicate that heterozygous truncating germline variants in SUFU alter SUFU-mediated repression and increase basal activity of HH signaling pathways, resulting in COMA and a neurodevelopmental disorder with largely benign course, but some variability of clinical phenotypes. The gene discussed is SUFU; the disease is neurodevelopmental disorder.